Atrion Co. (NASDAQ:ATRI - Get Free Report) shares saw an uptick in trading volume on Monday . 14,391 shares changed hands during mid-day trading, a decline of 23% from the previous session's volume of 18,792 shares.The stock last traded at $418.86 and had previously closed at $414.95.
Wall Street Analysts Forecast Growth
Separately, StockNews.com cut Atrion from a "hold" rating to a "sell" rating in a research report on Wednesday, May 1st.
Read Our Latest Analysis on Atrion
Atrion Trading Up 4.8 %
The firm has a 50-day moving average of $414.51 and a 200 day moving average of $366.07. The stock has a market capitalization of $765.60 million, a price-to-earnings ratio of 39.44 and a beta of 0.62.
Atrion (NASDAQ:ATRI - Get Free Report) last issued its quarterly earnings results on Thursday, February 29th. The medical instruments supplier reported $3.65 earnings per share (EPS) for the quarter. The firm had revenue of $43.58 million during the quarter. Atrion had a return on equity of 8.07% and a net margin of 11.46%.
Atrion Announces Dividend
The company also recently declared a quarterly dividend, which was paid on Friday, March 29th. Shareholders of record on Friday, March 15th were paid a dividend of $2.20 per share. This represents a $8.80 dividend on an annualized basis and a yield of 2.02%. The ex-dividend date of this dividend was Thursday, March 14th. Atrion's payout ratio is currently 79.78%.
Hedge Funds Weigh In On Atrion
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ATRI. Copeland Capital Management LLC boosted its stake in Atrion by 56.4% during the 4th quarter. Copeland Capital Management LLC now owns 86 shares of the medical instruments supplier's stock valued at $33,000 after purchasing an additional 31 shares in the last quarter. Quadrant Capital Group LLC bought a new stake in shares of Atrion during the 4th quarter worth $36,000. Harbor Investment Advisory LLC boosted its stake in shares of Atrion by 33.1% during the 4th quarter. Harbor Investment Advisory LLC now owns 189 shares of the medical instruments supplier's stock worth $72,000 after acquiring an additional 47 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Atrion by 592.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 270 shares of the medical instruments supplier's stock worth $102,000 after acquiring an additional 231 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in shares of Atrion during the 4th quarter worth $108,000. 66.19% of the stock is owned by institutional investors.
Atrion Company Profile
(
Get Free Report)
Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.
Read More
Before you consider Atrion, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atrion wasn't on the list.
While Atrion currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
